Tradersnewsletters.com, a leading online financial newsletter source, Reports on the following Companies: Generex Biotechnology Corp. (OTCQB: GNBT), DHS Holding, Co. (OTCPINK: DHSM), Hokutou Holdings International, Inc. (OTCPINK: HKTU), VuMee Inc. (OTCQB: VUME)
On Wednesday Generex Biotechnology Corp. (OTCQB: GNBT) gave us an overview of its Cancer Immunotherapy Product, AE37 that is under development at its wholly-owned subsidiary, Antigen Express, Inc. The company announced that a detailed update on development plans will be provided during the previously announced conference call scheduled for Thursday, January 31, 2013. They stated that “Antigen Express is in late Phase IIb clinical development for early stage breast cancer and has provided very encouraging interim results and Phase I testing in prostate cancer has been completed.”
The specific advantage of the cancer immunotherapy product AE37 is in early breast cancer by potentially stimulating the immune system to target HER2 (the target for Herceptin's effect) on breast cancer cells at low levels independent of immune type of the person. This follows in the footsteps of one of the most successful therapeutics ever developed for breast cancer (Herceptin), though AE37 potentially addresses an early breast cancer patient population of unmet need several times more common than those treated with Herceptin.
It should be noted that the pharmaceutical sector overall has been very active recently and leading the field is Johnson & Johnson (NYSE: JNJ),Pfizer, Inc. (NYSE: PFE), GlaxoSmithKline (NYSE: GSK), and AstraZeneca (NYSE: AZN).
Generex Biotechnology Corp. (OTCQB: GNBT) is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T-helper stimulation technologies in immunotherapy. One focuses on modification of peptides with Ii-Key to increase potency while a second relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T-helper cells and prevents the further growth of cancer cells.
Start receiving our Free Newsletter by visiting here: http://tradernewsletters.com/
Disclosure: We are not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit http://tradernewsletters.com/ for complete risks and disclosures.